en · de · es · fr · pt
sr9009-notes.peptides9000.com › Info › Background And Research Status — Hands-On Walkthrough

Background And Research Status — Hands-On Walkthrough

By Editorial Desk · published 2025-09-02 · last reviewed 2025-09-20 · Info

If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-09-20. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Research Status

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

SR9009 Handling and Quality Control

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Handling Storage and Quality Control

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Related pages on this site

Background and Pharmacological Mechanism

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Analytical Detection and Laboratory Handling

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

SR9009 Background and Mechanism

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

Supporting material

=== Ears === Some people find whispering or breathing softly in the ear to be pleasurable and relaxing, as well as licking, biting, caressing and/or kissing it especially the area of and behind the earlobe.

Angels of presence, praising God Seraphim – spirits of love Cherubim – spirits of harmony Thrones – record keepers of universal laws Angels of government, spreading light Dominions – spirits of wisdom and knowledge Virtues – angels of movement and free will Powers – angels of form and space Angels of revelation, able to communicate with humans Principalities – angels of time and personality Archangels – powerful angels superior to ordinary angels Angels – governors of spirits of nature

==== World Health Organization ==== On January 22, 2026, President Donald Trump completed the withdrawal of the United States from the World Health Organization (WHO), a specialized agency of the United Nations, a year after he signed Executive Order 14155 on January 20, 2025. As announced by the Department of Health and Human Services, the United States officially exited the organization, ending its 78-year membership and halting all U.S. funding and participation in the WHO's governance and activities. Although the organization hoped for a reconsideration the day after Trump's executive order, the administration continued with the decision. The administration justified the withdrawal by citing concerns about the WHO's handling of global health emergencies, including the COVID-19 pandemic, its resistance to reforms, and its failure to operate independently from inappropriate political influence of other WHO member states. In a joint statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F. Kennedy Jr., they said that the WHO "tarnished and trashed everything that America has done for it" and it "abandoned its core mission and acted repeatedly against the interests of the United States", including the failure to "hand over the American flag that hung in front of it". The United States still owes outstanding dues to the WHO from 2024 to 2025, raising questions about the legality and financial implications of the exit.

== Prevention == Hyperpigmentation can generally be prevented by inhibition of melanogenesis, with agents such as 4-Butylresorcinol, while the wound is healing. Notice that such agents might interfere with wound healing.

Dermatitis (characteristic "broad collar" rash known as casal collar) Hair loss Swelling Smooth, beefy red glossitis (tongue inflammation) Trouble sleeping Weakness Mental confusion or aggression Ataxia (lack of coordination), paralysis of extremities, peripheral neuritis (nerve damage) Diarrhea Dilated cardiomyopathy (enlarged, weakened heart) Sensitivity to radiation Eventually dementia J. Frostigs and Tom Spies—according to Cleary and Cleary—described more specific psychological symptoms of pellagra as:

Sources: en.wikipedia.org

Notes from published material

The Transitional Federal Government (TFG) was the internationally recognised government of Somalia until 20 August 2012, when its tenure officially ended. It was established as one of the Transitional Federal Institutions (TFIs) of government as defined in the Transitional Federal Charter (TFC) adopted in November 2004 by the Transitional Federal Parliament (TFP). The Transitional Federal Government officially comprised the executive branch of government, with the TFP serving as the legislative branch. The government was headed by the President of Somalia, to whom the cabinet reported through the Prime Minister. However, it was also used as a general term to refer to all three branches collectively. Owing to a lack of funding and human resources, an arms embargo that made it difficult to reestablish a national security force, and general indifference on the part of the international community, Yusuf found himself obliged to deploy thousands of troops from Puntland to Mogadishu to sustain the battle against insurgent elements in the southern part of the country. Financial support for this effort was provided by the autonomous region's government. This left little revenue for Puntland's own security forces and civil service employees, leaving the territory vulnerable to piracy and terrorist attacks. On 29 December 2008, Yusuf announced before a united parliament in Baidoa his resignation as President of Somalia.

== Psychoactive use == In Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs, Freye asserts, "Few substances have received as many severely negative recreational experience reports as has Datura." The overwhelming majority of those who describe their use of Datura find their experiences extremely unpleasant—both mentally and often physically. However, anthropologists have found that indigenous groups, with a great deal of experience and detailed knowledge of Datura, have been known to use Datura spiritually (including the Navajo and especially the Havasupai). Adequate knowledge of Datura's properties is necessary to facilitate a safe experience. The ancient inhabitants of what became central and southern California used to ingest Datura to "commune with deities through visions". The Southern Paiute believe Datura can help locate missing objects. In ancient Mexico, Datura also played an important role in the religion of the Aztecs and the practices of their medicine men and necromancers. It was reportedly used by the Aztecs for ritual sacrifice and malevolent purposes as well. In modern-day Mexico, some Datura species are still used for sorcery and other occult practices, mostly in the southern region of Veracruz, specifically in the city of Catemaco. In Afghanistan, it was used by the Malang as a shamanic initiation rite and to contact the "other-world". Bernardino de Sahagún, in around 1569, called attention to Datura in these words: "It is administered in potions in order to cause harm to those who are objects of hatred.

=== Other conditions === Modafinil has been investigated for several other conditions with inconclusive or preliminary results. Preliminary research is examining modafinil for excessive daytime sleepiness in myotonic dystrophy, though it is not approved for this use and results are debated. Modafinil has also been studied for disorders of consciousness, but observational reports have produced mixed results.

=== 7 April === The RSF launched a drone attack on Dongola Airport, destroying a fuel storage facility. Three people were killed by RSF shelling on Abu Shouk IDP camp. Several others were killed in an joint RSF and SPLM-N (al-Hilu) attack in Rashad, South Kordofan.

== Regulatory involvement == RQA has links with DEFRA, in particular with a joint code of practice for veterinary activities. Members of RQA committees regulatory attend and contribute to stakeholder meetings run by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK and the European Medicines Agency (EMA) in Europe. RQA attends the annual Research and Development Forum run by the NHS.

Sources: en.wikipedia.org

Background from the literature

However, since opioid antagonists also block the beneficial effects of opioid analgesics, they are generally useful only for treating overdose, with use of opioid antagonists alongside opioid analgesics to reduce side effects, requiring careful dose titration and often being poorly effective at doses low enough to allow analgesia to be maintained. Naltrexone does not appear to increase risk of serious adverse events, which confirms the safety of oral naltrexone. Mortality or serious adverse events due to rebound toxicity in patients with naloxone were rare.

As such, PBPK modeling can be used, inter alia, to evaluate the involvement of carrier-mediated transport, clearance saturation, enterohepatic recirculation of the parent compound, extra-hepatic/extra-gut elimination; higher in vivo solubility than predicted in vitro; drug-induced gastric emptying delays; gut loss and regional variation in gut absorption.

Darren Keith McGuire, MD, MHSc is an American cardiologist and clinical trialist specializing in cardiovascular disease prevention and cardiometabolic medicine, particularly the relationship between diabetes and heart disease. He is a Distinguished Teaching Professor of Internal Medicine in the Division of Cardiology at the University of Texas Southwestern Medical Center. He also serves as lead physician of the Parkland Health cardiology clinics and holds the Jere H. Mitchell Distinguished Chair in Cardiovascular Science.

The stronger the interactions between the polar analyte and the polar stationary phase (relative to the mobile phase) the longer the elution time. The interaction strength depends on the functional groups part of the analyte molecular structure, with more polarized groups (e.g., hydroxyl-) and groups capable of hydrogen bonding inducing more retention. Coulombic (electrostatic) interactions can also increase retention. Use of more polar solvents in the mobile phase will decrease the retention time of the analytes, whereas more hydrophobic solvents tend to increase retention times.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network